



Contents lists available at ScienceDirect

Chinese Chemical Letters

journal homepage: www.elsevier.com/locate/cclet



Corrigendum to “An overview of polymeric nanomicelles in clinical trials and on the market” [Chinese Chemical Letters 32 (2021) 243-257]



Xue Zheng^a, Jizhen Xie^c, Xing Zhang^a, Weiting Sun^a, Heyang Zhao^a, Yantuan Li^{a,b,*},
Cheng Wang^{a,b,*}

^a Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China

^b Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China

^c Shandong Center for Food and Drug Evaluation and Certification, Ji'nan 250013, China

The authors regret <According to ref. [90], the sentence on page 249 “A Phase I/II trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in Taiwan and Singapore (n = 22) [90].” should be revised to “A Phase I/II trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in the United States and Europe (n = 22) [90].”>.

The authors would like to apologise for any inconvenience caused.

DOI of original article: [10.1016/j.ccl.2020.11.029](https://doi.org/10.1016/j.ccl.2020.11.029)

* Corresponding authors at: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.

E-mail addresses: yantuanli@ouc.edu.cn (Y. Li), cheng13980029671@163.com (C. Wang).

<https://doi.org/10.1016/j.ccl.2024.110545>

1001-8417/© 2024 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.